Drug intelligence / Profile preview

GCF20211

Development stage: Preclinical
Lead developer: Guangzhou Green Cross Pharmaceutical
Modality: Small Molecules

Overview

GCF20211 is a small molecule therapeutic candidate being developed by Guangzhou Green Cross Pharmaceutical for the treatment of insomnia, specifically targeting patients with difficulty falling asleep. Classified as a Class 2.2 improved new drug under the NMPA regulatory framework in China, the program likely involves a novel formulation or delivery system of a known sedative-hypnotic agent designed to optimize pharmacokinetic properties or clinical outcomes. The asset is currently in the preclinical stage of development.

Beyond the preview

Go deeper on GCF20211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCF20211.

Explore the full profile